Skip to main content
. Author manuscript; available in PMC: 2023 Apr 29.
Published in final edited form as: J Neurosurg. 2021 Oct 29;136(6):1567–1575. doi: 10.3171/2021.6.JNS21925

Figure 6:

Figure 6:

SMR threshold percentages and the ideal treatment paradigm. Based on this patient series, for highly diffuse tumors, resection of at least 30% of the FLAIR hyperintensity beyond the contrast enhancement showed a survival benefit, with no data supporting SMR above 99% of the FLAIR region to be beneficial. For moderately diffuse tumors, resection of at least 10% of the FLAIR hyperintensity beyond the contrast enhancement showed a survival benefit, with no data supporting that SMR above 60% provides further benefit. For nodular tumors, only resection between 10% and 29% of the FLAIR hyperintensity beyond the contrast enhancement showed a survival benefit.